Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma

[1]  R. Schlossman,et al.  Bone marrow transplantation in multiple myeloma. , 1999, Current opinion in oncology.

[2]  M. Gore,et al.  A randomized trial of maintenance interferon following high‐dose chemotherapy in multiple myeloma: long‐term follow‐up results , 1998, British journal of haematology.

[3]  H. Deeg,et al.  Malignancies after hematopoietic stem cell transplantation: many questions, some answers. , 1998, Blood.

[4]  B. Barlogie,et al.  Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. , 1997, Blood.

[5]  R. Marcus,et al.  Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. , 1996, Blood.

[6]  B. Barlogie,et al.  Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma , 1996, British journal of haematology.

[7]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[8]  R. Storb,et al.  High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Prentice,et al.  Autologous stem cell transplantation in multiple myeloma: Results of the european group for bone marrow transplantation , 1995, Stem cells.

[10]  R. Bataille,et al.  Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the french registry on autologous transplantation in multiple myeloma , 1995, Blood.

[11]  B. Samuels,et al.  High-dose intravenous melphalan: a review. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  T. Hickish,et al.  High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Gore,et al.  High-dose melphalan for multiple myeloma: long-term follow-up data. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Van Dyk,et al.  Radiosensitivity of human clonogenic myeloma cells and normal bone marrow precursors: effect of different dose rates and fractionation. , 1994, International journal of radiation oncology, biology, physics.

[15]  M. Dimopoulos,et al.  Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. , 1993, Blood.

[16]  D. Reece,et al.  Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide. , 1993, Bone marrow transplantation.

[17]  S. Forman,et al.  High-dose etoposide (VP-16)-containing preparatory regimens in allogeneic and autologous bone marrow transplantation for hematologic malignancies. , 1992, Seminars in oncology.

[18]  N. Ifrah,et al.  Double-intensive therapy in high-risk multiple myeloma. , 1992, Blood.

[19]  B. Barlogie,et al.  Autologous bone marrow transplantation for multiple myeloma. , 1992, Hematology/oncology clinics of North America.

[20]  B. Mazières,et al.  Intensive combined therapy for previously untreated aggressive myeloma. , 1992, Blood.

[21]  S. Jagannath,et al.  High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma , 1987 .

[22]  M. Slevin,et al.  Multiple myeloma treated with high dose intravenous melphalan , 1987, British journal of haematology.

[23]  D. Findley,et al.  Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. , 1987, Blood.

[24]  Zander,et al.  High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. , 1986, Blood.

[25]  T. Mcelwain,et al.  HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA , 1983, The Lancet.

[26]  G. Goucher,et al.  Melphalan-induced pulmonary interstitial fibrosis. , 1980, Chest.

[27]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[28]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[30]  C. Solano,et al.  Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry , 1998, Bone Marrow Transplantation.

[31]  K. Anderson,et al.  Bone marrow transplantation in multiple myeloma. , 1997, Cancer investigation.

[32]  S. Sutcliffe,et al.  Peripheral neuropathy following high-dose etoposide and autologous bone marrow transplantation. , 1994, Bone marrow transplantation.

[33]  B. Barlogie,et al.  High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. , 1994, Blood.

[34]  S. Nimer,et al.  Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma. , 1994, Bone marrow transplantation.

[35]  B. Barlogie,et al.  Prognostic factors with high-dose melphalan for refractory multiple myeloma. , 1988, Blood.